FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Spectrum is committed to helping you and your patients access FOLOTYN

Spectrum Therapy Access Resources (STAR®)

Spectrum Therapy Access Resources

STAR is a reimbursement support, co-pay assistance, and patient assistance program designed to help patients and health care professionals gain appropriate access to certain Spectrum products.

Call 1-888-53-STAR-7 OR 1-888-537-8277

Spectrum Pharmaceuticals, Inc.® does not guarantee coverage and/or reimbursement for its products. Coverage, coding, and reimbursement policies vary significantly by payer, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. Healthcare professionals should always verify coverage, coding, and reimbursement guidelines on a payer and patient-specific basis. Spectrum Pharmaceuticals, Inc. reserves the right to change eligibility guidelines, terminate, or modify the STAR program at any time for any reason.